Results 61 to 70 of about 289,325 (184)

P/Q-type calcium-channel blockade in the periaqueductal gray facilitates trigeminal nociception: a functional genetic link for migraine? [PDF]

, 2002
The discovery of mis-sense mutations in the alpha1A subunit of the P/Q-type calcium channel in patients with familial hemiplegic migraine indicates the potential involvement of dysfunctional ion channels in migraine.
Goadsby, PJ, Yolande E. Knight, Knight, Yolande E., Knight, YE, Goadsby, Peter J., Bartsch, Thorsten, Peter J. Goadsby, Kaube, Holger, Holger Kaube, Kaube, H, Thorsten Bartsch, Bartsch, T   +11 more
core   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series. [PDF]

, 2016
BACKGROUND: Refractory migraine is a challenging condition with great impact on health related quality of life. Intravenous (IV) ketamine has been previously used to treat various refractory pain conditions.
Lipton, Richard B., Lauritsen, Clinton, Ashina, Sait, Mazuera, Santiago   +3 more
core   +2 more sources

Peripheral targets for neuropathic pain

British Journal of Pharmacology, EarlyView.
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour, Cosmin I. Ciotu, Felix J. Resch, Michael J. M. Fischer   +3 more
wiley   +1 more source

Response to treatment with Botulinum toxin-A in patients with Refractory Chronic Migraine [PDF]

Iranian South Medical Journal
Background: Migraine is one of the common causes of headache, and refractory migraine imposes a significant eco-nomic burden; therefore, it is important to find a proper treatment method for this condition.
Amir Molaei, Mehara Hemmati, Shahrzad Izadi, Fatemeh Paknazar, Saeid Shakeri, Hamidreza Hemmati   +5 more
doaj  

Impact of neuromodulation targeting the trigeminocervical complex on pain reduction in refractory chronic migraine

Headache Medicine
Introduction Refractory chronic migraine is associated with a high degree of disability and persistent attacks, being characterized by central sensitization processes in the trigeminocervical complex (TCC).
Lucas Matheus Mendonça Santos, Guilherme de Sá Rezende, Ana Beatriz Gomes Oliveira, Luísa Araújo Marinho Silva, Breno Souto Aldeman Duarte de Assis, Emanuel da Costa Alvez, Vitor Emanuel Ferreira de Almeida   +6 more
doaj   +2 more sources

Subspecialty headache clinic visit reduced healthcare utilization in patients with migraine: Single institution retrospective cohort study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective This study aimed to evaluate whether care in a subspecialty headache center, compared with a general neurology clinic, was associated with lower 90‐day unplanned healthcare utilization (HCU) in patients with migraine and to identify patient‐level factors associated with higher unplanned HCU. Background Migraine is a common, disabling
Megan Trenz, Raja Narendra Divakar Addanki, Jason Raad, Robert Kaniecki, Janel Hanmer, Manisha Jhamb, Wesley T. Kerr, Parthasarathy D. Thirumala   +7 more
wiley   +1 more source

Development of a machine learning (ML) model to predict 3‐month response to CGRP monoclonal antibodies in migraine: A pilot evaluation of physician‐ML model interaction

Headache: The Journal of Head and Face Pain, EarlyView.
Plain Language Summary Monoclonal antibodies that target calcitonin gene‐related peptide (CGRP‐mAbs) are effective treatments for preventing migraine in many patients but are expensive, and physicians cannot easily predict which patients will benefit from them.
Masahito Katsuki, Muneto Tatsumoto, Tomokazu Shimazu, Yasuhiko Matsumori, Marina Romozzi, Omid Kohandel Gargari, Alicia Gonzalez‐Martinez, Woo‐Seok Ha, Yutaro Fuse, Shiho Suzuki, Saro Kobayashi, Tomohiko Shiina, Mukuto Shioda, Hiroaki Fujita, Koichi Hirata, Yuya Kano, Ryosuke Fukazawa, Jackson T. S. Cheung, Siobhán O'Connor, Tomás Ward, Kieran Moran, Keisuke Suzuki   +21 more
wiley   +1 more source

Cerebral Venous Thrombosis with Migraine-Like Headache and the Trigeminovascular System

Case Reports in Neurological Medicine, 2016
Cerebral venous thrombosis- (CVT-) associated headache is considered a secondary headache, commonly presenting as intracranial hypertension headache in association with seizures and/or neurological signs. However, it can occasionally mimic migraine.
Fábio A. Nascimento, Marília Grando Sória, Vanessa Rizelio, Pedro A. Kowacs   +3 more
doaj   +1 more source